摘要
目的:观察羟苯磺酸钙联合依帕司他对2型糖尿病周围神经病变患者的临床疗效。方法:选取2015年1-12月笔者所在医院内分泌科门诊的2型糖尿病周围神经病变患者350例,按照就诊顺序进行分组,将奇数就诊号设置为治疗组,共177例;将偶数就诊号设置为对照组,共173例。两组均给予控制血糖治疗,对照组在此基础上给予依帕司他,治疗组在对照组基础上口服羟苯磺酸钙,均治疗12周。统计两组治疗前后密歇根糖尿病神经病变量表(MDNS)和密歇根神经病变筛查量表(MNSI)评分,对比两组临床疗效。结果:治疗12周后,对照组总有效率为84.97%,显著低于治疗组的96.04%,差异有统计学意义(χ^2=12.560,P=0.000)。治疗12周后,两组MDNS和MNSI评分均较治疗前降低,差异均有统计学意义(P<0.05)。治疗组治疗后MDNS和MNSI评分均低于对照组,差异均有统计学意义(P<0.05)。结论:羟苯磺酸钙联合依帕司他治疗2型糖尿病周围神经病变的效果优于单用依帕司他治疗。
Objective:To observe the effect of Calcium Dobesilate combined with Epalrestat in the treatment of type 2 diabetic peripheral neuropathy.Method:From January to December 2015,350 patients with type 2 diabetic peripheral neuropathy were selected from the endocrinology department of our hospital.The patients were grouped according to the treatment order,and the odd number was set as the treatment group,177 cases in total.The even number was set as the control group,173 cases in total.Both groups were treated with glucose control,and the control group was treated with Epalrestat on this basis,and the treatment group was treated with Calcium Dobesilate orally on the basis of the control group,and patients were treated for 12 weeks.Before and after treatment,the Michigan diabetic neuropathy scale(MDNS)and the Michigan neuropathy screening instrument(MNSI)were analyzed between the two groups,and the clinical efficacy of the two groups was compared.Result:After 12 weeks of treatment,the total effective rate of the control group was 84.97%,which was significantly lower than 96.04%of the treatment group,and the difference was statistically significant(χ^2=12.560,P=0.000).After 12 weeks of treatment,the scores of the MDNS and MNSI of the two groups were significantly lower than those before treatment,and the differences were statistically significant(P<0.05).And the scores of MDNS and MSNI of the treatment group were lower than those of the control group after treatment,and the differences were statistically significant(P<0.05).Conclusion:The efficacy of Calcium Dobesilate combined with Epalrestat in the treatment of type 2 diabetic peripheral neuropathy is better than that of Epalrestat alone.
作者
李永梅
宋文娟
刘清
饶小胖
LI Yongmei;SONG Wenjuan;LIU Qing;RAO Xiaopang(Qingdao Hospital Affiliated to Shandong First Medical University,Qingdao 266109,China;不详)
出处
《中外医学研究》
2020年第6期54-56,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
